<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "axitinib tab">
<dose><value>2</value>
<value>3</value>
<value>5</value>
<value>7</value>
<value>10</value>
</dose>
<route><value>PO</value>
</route>
<strength><value>1 mg </value>
<value>5 mg</value>
</strength>
<frequency><value>BID</value>
</frequency>
<instruction></instruction>
<volume></volume>
<units><value>mg</value>
</units>
<Population><value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Child-Pugh class B: starting dose should be decreased by approximately half in moderate impairment. If patients tolerate starting dose and experience no adverse reaction greater than grade 2 for two consecutive weeks, are normotensive and are not receiving antihypertensives, dose may be increased from 5mg BID to 7 mg BID. Subsequently, using the same criteria, patients tolerating 7 mg BID may have dose increased to a maximum of 10 mg BID. </value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6401</value>
<value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=6402</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>Formulary with Restrictions.</value>
</AHSFormularyStatus>
<AHFSName><value>Antineoplastic Agents</value>
</AHFSName>
<HighAlert><value>YES</value>
</HighAlert>
</drug>